163 related articles for article (PubMed ID: 38475819)
1. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade.
Cho SM; Park YG; Lee JM; Byun JY; Lee JM; Lee KY; Park GS; Kim HS; Lee BY; Lee KH; Song KS
Eur Radiol; 2007 Feb; 17(2):409-17. PubMed ID: 16786320
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
Dai N; Liu H; Deng S; Sang S; Wu Y
Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
[No Abstract] [Full Text] [Related]
5.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
6. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
7. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
8. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.
Werner RA; Kroiss M; Nakajo M; Mügge DO; Hahner S; Fassnacht M; Schirbel A; Bluemel C; Higuchi T; Papp L; Zsótér N; Buck AK; Bundschuh RA; Lapa C
Endocrine; 2016 Sep; 53(3):791-800. PubMed ID: 27138903
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
11. Intratumor Heterogeneity Assessed by
Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
Acad Radiol; 2020 Aug; 27(8):e183-e192. PubMed ID: 31761665
[TBL] [Abstract][Full Text] [Related]
12. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
13. Associations Between [
Surov A; Meyer HJ; Höhn AK; Winter K; Sabri O; Purz S
Mol Imaging Biol; 2019 Apr; 21(2):368-374. PubMed ID: 29931433
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma.
Matsuura T; Otsuka I; Ouchi T; Ouchi E; Asano R; Miyasaka N
Taiwan J Obstet Gynecol; 2021 Mar; 60(2):305-310. PubMed ID: 33678332
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of
Wang J; Yu X; Shi A; Xie L; Huang L; Su Y; Zha J; Liu J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14535-14547. PubMed ID: 37567986
[TBL] [Abstract][Full Text] [Related]
16. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
17. A pilot study for texture analysis of
Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.
Chung YS; Kim Y; Kim HS; Lee JY; Kang WJ; Kim S; Kim SW
J Gynecol Oncol; 2022 May; 33(3):e28. PubMed ID: 35128858
[TBL] [Abstract][Full Text] [Related]
19. [
Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38467921
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.
Chung HH; Lee M; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Eur Radiol; 2017 Nov; 27(11):4510-4515. PubMed ID: 28593431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
